Search Results

Pharmacokinetics, Safety, and Tolerability of Once-Daily Darunavir With Cobicistat and Weekly Isoniazid/ Rifapentine.

• Authors : Brooks, Kristina M.; Pau, Alice K.; Swaim, Doris

• Source: JAIDS: Journal of Acquired Immune Deficiency Syndromes. 12/15/2023, Vol. 94 Issue 5, p468-473. 6p.

Record details

No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up.

• Authors : Calza, Leonardo (AUTHOR); Borderi, Marco (AUTHOR); Colangeli, Vincenzo (AUTHOR)

Subjects: CAROTID intima-media thickness; DOPPLER ultrasonography; ANTIRETROVIRAL agents

• Source: Infectious Diseases. Apr2020, Vol. 52 Issue 4, p249-256. 8p. 1 Diagram, 2 Charts.

Record details

Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV.

• Authors : Momper, Jeremiah D. PharmD, (AUTHOR); Wang, Jiajia MS (AUTHOR); Stek, Alice (AUTHOR)

• Source: JAIDS: Journal of Acquired Immune Deficiency Syndromes. Mar2022, Vol. 89 Issue 3, p303-309. 7p.

Record details

Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.

• Authors : Sun, Liqin (AUTHOR); He, Yun (AUTHOR); Xu, Liumei (AUTHOR)

• Source: JAIDS: Journal of Acquired Immune Deficiency Syndromes. Oct2022Supplement, Vol. 91, pS8-S15. 8p.

Record details

Reduced exposure to darunavir and cobicistat in HIV‐1‐infected pregnant women receiving a darunavir/cobicistat‐based regimen.

• Authors : Crauwels, HM (AUTHOR); Osiyemi, O (AUTHOR); Zorrilla, C (AUTHOR)

Subjects: COMBINATION drug therapy; COMPARATIVE studies; GESTATIONAL age

• Source: HIV Medicine. May2019, Vol. 20 Issue 5, p337-343. 7p.

Record details

Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir.

• Source: ASHP Patient Medication Information - English Version. Mar2022, p1-1. 1p.

Record details

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study.

• Authors : Gori, Andrea; Antinori, Andrea; Vergori, Alessandra

• Source: JAIDS: Journal of Acquired Immune Deficiency Syndromes. Jul2020, Vol. 84 Issue 3, p290-294. 5p.

Record details

Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.

• Authors : Salama, Engie (AUTHOR); Hill, Lucas (AUTHOR); Patel, Nimish (AUTHOR)

• Source: JAIDS: Journal of Acquired Immune Deficiency Syndromes. Dec2021, Vol. 88 Issue 4, p389-392. 4p.

Record details

Cobicistat as a Pharmacoenhancer in Pregnancy and Postpartum: Progress to Date and Next Steps.

• Authors : Eke, Ahizechukwu C.; Mirochnick, Mark H.

Subjects: COMBINATION drug therapy; GLYCOPROTEINS; PEPTIDES

• Source: Journal of Clinical Pharmacology. Jun2019, Vol. 59 Issue 6, p779-783. 5p.

Record details

Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.

• Authors : Llibre, JM; Montoliu, A; Miró, JM

Subjects: MENTAL illness risk factors; RALTEGRAVIR; ABACAVIR

• Source: HIV Medicine. Mar2019, Vol. 20 Issue 3, p237-247. 11p.

Record details